IP Library › Granted Patent US 12,600,780
Granted Patent B2
US 12,600,780 · App. 18/512,432 · Granted Apr 14, 2026

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

Inventors: Eric Smith (New York, NY); Nicholas J. Papadopoulos (LaGrangeville, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/2809C07K16/2887A61K2039/505C07K2317/21C07K2317/31C07K2317/33C07K2317/35C07K2317/734C07K2317/74C07K2317/92Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,780
App. No.
18/512,432
Granted
Apr 14, 2026
Kind
B2
Abstract

The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

Claims (24)

1 . An antigen-binding molecule that binds human CD3, wherein the antigen-binding molecule comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 1052, 1054 and 1056, respectively, and a light chain variable region (LCVR) comprising three light chain complementarity determining regions, LCDR1, LCDR2 and LCDR3, comprising the amino acid sequences of SEQ ID NO: 1236, AAS and SEQ ID NO: 1240, respectively.

2 . The antigen-binding molecule of claim 1 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1050.

3 . The antigen-binding molecule of claim 2 that is an antibody or antigen-binding fragment thereof.

4 . A pharmaceutical composition comprising the antigen-binding molecule of claim 2 , and a pharmaceutically acceptable carrier or diluent.

5 . The antigen-binding molecule of claim 1 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 1234.

6 . The antigen-binding molecule of claim 5 that is an antibody or antigen-binding fragment thereof.

7 . A pharmaceutical composition comprising the antigen-binding molecule of claim 5 , and a pharmaceutically acceptable carrier or diluent.

8 . The antigen-binding molecule of claim 1 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1050, and the LCVR comprises the amino acid sequence of SEQ ID NO: 1234.

9 . The antigen-binding molecule of claim 8 that is an antibody or antigen-binding fragment thereof.

10 . A pharmaceutical composition comprising the antigen-binding molecule of claim 8 , and a pharmaceutically acceptable carrier or diluent.

11 . The antigen-binding molecule of claim 8 , wherein the antigen-binding molecule comprises a scFv comprising the HCVR and the LCVR.

12 . The antigen-binding molecule of claim 1 that is an antibody or antigen-binding fragment thereof.

13 . A pharmaceutical composition comprising the antigen-binding molecule of claim 1 , and a pharmaceutically acceptable carrier or diluent.

14 . The antigen-binding molecule of claim 1 , wherein the antigen-binding molecule comprises a single chain variable fragment (scFv) comprising the HCVR and the LCVR.

15 . A pharmaceutical composition comprising the antigen-binding molecule of claim 14 , and a pharmaceutically acceptable carrier or diluent.

16 . A method of treating cancer in a subject in need thereof, the method comprising administering the antigen-binding molecule of claim 1 to the subject.

17 . A pair of nucleic acid molecules comprising:

a first nucleic acid molecule encoding a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 1052, 1054 and 1056, respectively; and

a second nucleic acid molecule encoding a light chain variable region (LCVR) comprising three light chain complementarity determining regions, LCDR1, LCDR2 and LCDR3, comprising the amino acid sequences of SEQ ID NO: 1236, AAS and SEQ ID NO: 1240, respectively.

18 . The pair of nucleic acid molecules of claim 17 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1050, and the LCVR comprises the amino acid sequence of SEQ ID NO: 1234.

19 . An isolated host cell comprising the pair of nucleic acid molecules of claim 17 .

20 . A method of producing an antigen-binding molecule that binds human CD3, the method comprising:

(a) culturing a host cell comprising a first nucleic acid molecule encoding a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 1052, 1054 and 1056, respectively, and a second nucleic acid molecule encoding a light chain variable region (LCVR) comprising three light chain complementarity determining regions, LCDR1, LCDR2 and LCDR3, comprising the amino acid sequences of SEQ ID NO: 1236, AAS and SEQ ID NO: 1240, respectively, under conditions permitting production of the antigen-binding molecule; and

(b) recovering the antigen-binding molecule so produced.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2024
From: SMITH, ERIC; PAPADOPOULOS, NICHOLAS J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067173/0798 →
Continuity (8)
Continuation 17355532 · Jun 23, 2021
Division 15489666 · Apr 17, 2017
Continuation 14031075 · Sep 19, 2013
Provisional Application 61827098 · May 24, 2013
Provisional Application 61763110 · Feb 11, 2013
Provisional Application 61753461 · Jan 17, 2013
Provisional Application 61704029 · Sep 21, 2012
Related Publication 20240352124A1 · Oct 24, 2024
References Cited (209)
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5658570A · Newman et al. · 1997 [cited by applicant]
US 5677180A · Robinson et al. · 1997 [cited by applicant]
US 5721108A · Robinson et al. · 1998 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5776456A · Anderson et al. · 1998 [cited by applicant]
US 5843439A · Anderson et al. · 1998 [cited by applicant]
US 6120767A · Robinson et al. · 2000 [cited by applicant]
US 6224866B1 · Barbera-Guillem · 2001 [cited by applicant]
US 6399061B1 · Anderson et al. · 2002 [cited by applicant]
US 6455043B1 · Grillo-Lopez · 2002 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6551592B2 · Lindhofer et al. · 2003 [cited by applicant]
US 6652852B1 · Robinson et al. · 2003 [cited by applicant]
US 6682734B1 · Anderson et al. · 2004 [cited by applicant]
US 6893625B1 · Robinson et al. · 2005 [cited by applicant]
US 7151164B2 · Hansen et al. · 2006 [cited by applicant]
US 7214775B2 · Hanai et al. · 2007 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 7879984B2 · Martin et al. · 2011 [cited by applicant]
US 8076459B2 · Hofmeister et al. · 2011 [cited by applicant]
US 8097713B2 · Martin et al. · 2012 [cited by applicant]
US 8329181B2 · Martin et al. · 2012 [cited by applicant]
US 8597648B2 · Guo et al. · 2013 [cited by applicant]
US 9657102B2 · Smith et al. · 2017 [cited by applicant]
US 10550193B2 · Smith et al. · 2020 [cited by applicant]
US 10662244B2 · Smith et al. · 2020 [cited by applicant]
US 11072656B2 · Smith et al. · 2021 [cited by applicant]
US 11155621B2 · Smith et al. · 2021 [cited by applicant]
US 11590223B2 · Brownstein et al. · 2023 [cited by applicant]
US 12054557B2 · Varghese et al. · 2024 [cited by applicant]
US 20030026804A1 · Grillo-Lopez · 2003 [cited by applicant]
US 20040093621A1 · Shitara et al. · 2004 [cited by applicant]
US 20040167319A1 · Teeling et al. · 2004 [cited by applicant]
US 20050025764A1 · Watkins et al. · 2005 [cited by applicant]
US 20050053602A1 · Brunetta · 2005 [cited by applicant]
US 20050191297A1 · Brunetta · 2005 [cited by applicant]
US 20050271658A1 · Brunetta et al. · 2005 [cited by applicant]
US 20060024295A1 · Brunetta · 2006 [cited by applicant]
US 20060110387A1 · Brunetta · 2006 [cited by applicant]
US 20060121032A1 · Dahiyat et al. · 2006 [cited by applicant]
US 20060193852A1 · Dorken et al. · 2006 [cited by applicant]
US 20060233797A1 · Gujrathi · 2006 [cited by applicant]
US 20060240007A1 · Sanders · 2006 [cited by applicant]
US 20060263355A1 · Quan et al. · 2006 [cited by applicant]
US 20070014720A1 · Gazit-Bornstein et al. · 2007 [cited by applicant]
US 20070020259A1 · Hansen et al. · 2007 [cited by applicant]
US 20070081993A1 · Kufer et al. · 2007 [cited by applicant]
US 20090022738A1 · Hofmeister et al. · 2009 [cited by applicant]
US 20090035322A1 · Martin et al. · 2009 [cited by applicant]
US 20100178298A1 · Lindhofer · 2010 [cited by applicant]
US 20100183554A1 · Mach et al. · 2010 [cited by applicant]
US 20100183615A1 · Kufer et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20150166661A1 · Chen et al. · 2015 [cited by applicant]
US 20150203579A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150266966A1 · Smith et al. · 2015 [cited by applicant]
US 20160168247A1 · Van Den Brink et al. · 2016 [cited by applicant]
EP 1400534A1 · 2004 [cited by applicant]
EP 1176981B1 · 2005 [cited by applicant]
EP 1185299B1 · 2007 [cited by applicant]
EP 2500353A2 · 2012 [cited by applicant]
EP 2918604A1 · 2015 [cited by applicant]
WO 04106380A2 · 2004 [cited by applicant]
WO 04106383A1 · 2004 [cited by applicant]
WO 05000901A2 · 2005 [cited by applicant]
WO 05040220A1 · 2005 [cited by applicant]
WO 05118635A3 · 2005 [cited by applicant]
WO 06130458A2 · 2006 [cited by applicant]
WO 07024715A2 · 2007 [cited by applicant]
WO 07042261A2 · 2007 [cited by applicant]
WO 07093630A1 · 2007 [cited by applicant]
WO 08076379A3 · 2008 [cited by applicant]
WO 08119567A2 · 2008 [cited by applicant]
WO 09018411A1 · 2009 [cited by applicant]
WO 09023540A1 · 2009 [cited by applicant]
WO 09030368A1 · 2009 [cited by applicant]
WO 09106096A1 · 2009 [cited by applicant]
WO 10151792A1 · 2010 [cited by applicant]
WO 11090762A1 · 2011 [cited by applicant]
WO 11163566A1 · 2011 [cited by applicant]
WO 12073985A1 · 2012 [cited by applicant]
WO 120109285A2 · 2012 [cited by applicant]
WO 12162067A2 · 2012 [cited by applicant]
WO 13072406A1 · 2013 [cited by applicant]
WO 13072415A1 · 2013 [cited by applicant]
WO 14012085A2 · 2014 [cited by applicant]
WO 14022540A1 · 2014 [cited by applicant]
WO 14047231A1 · 2014 [cited by applicant]
WO 14121087A1 · 2014 [cited by applicant]
WO 15006749A2 · 2015 [cited by applicant]
WO 15143079A1 · 2015 [cited by applicant]
Advani et al., “New immune strategies for the treatment of acute pymphoblastic leukemia: antibodies and chimeric antigen receptors,” Hematology, vol. 2013 (No. 1): (Dec. 1, 2013). [cited by applicant]
Aklilu et al., “Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma,” Annals of Oncology 15: 1109-1114; Chicago, IL (2004). [cited by applicant]
Anonymous, “Clinical Trails Register: A Phase I Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, and REGN2810, and anti-programmed death-1 (PD-1) monoclonal an… [cited by applicant]
Anonymous, “Study of REGN2810 and REGN1979 in Patients with Lymphoma or Acute Lymphoblastic Leukemia.” [Retrieved from the Internet Mar. 15, 2017: <URL: https://www.api.liveclinicaltrials.com/trialpage?dcn=10963&city=Ba… [cited by applicant]
Bannerji et al., “Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy,” Blood, vol. 128 (2… [cited by applicant]
Bargou et al., “Tumor egression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody,” Science Magazine, vol. 321: 974-977, (2008). [cited by applicant]
Boehrer et al., “Cytotoxic effects of the trifunctional bispecific antibody FBTACI5 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms,” Anti-Cancer Drugs, 22:519-530, (2011). [cited by applicant]
Buhmann et al., “Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion,” Bone Marrow Transplantation, 43:383-397, (… [cited by applicant]
Carter, “Potent Antibody Therapeutics by Design,” Journal of Immunology, Nature Pub. Group, 6:343-357, (2006). [cited by applicant]
Chatenoud et al., “CD3-specific antibodies: a portal to the treatment of autoimmunity,” Nature, vol. (7):622-632, (Aug. 2007). [doi:10.1038/nri2134: <URL: www.nature.com/reviews/immunol>]. [cited by applicant]
Chen et al., “Strategies for Generating Diverse Antibody Reportoires Using Transgenic Animals Expressing Human Antibodies,” Front. Immunol. Vol. 9, Article 460; Mar. 2018; 7 pages. doi: 10.3389/fimmu.2018.00460. [cited by applicant]
Conrad et al., “TCR and CD3 Antibody Cross-Reactivity in 44 Species,” Cytometry Part A, 71A:925-933, (2007). [cited by applicant]
Damschroder et al., “Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies,” Molecular Immunology, vol. 41:985-1000, (2004). [cited by applicant]
Frey et al., “Cytokine release syndrome: Who is at risk and how to treat,” Best Practice & Research Clinical Haematology, vol. 30 (No. 4): 336-340, (Dec. 2017). [Retrieved from the Internet Sep. 11, 2023: <URL: https://… [cited by applicant]
Gall et al., “T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro”, Experimental Hematology, 33(4):452-459,… [cited by applicant]
Grubb, “Human Immunoglobulin Allotypes and Mendelian Polymorphisms of the Human Immunoglobulin Genes,” in Oss CJ, Regenmortel MHV (eds); Immunochemistry, New York, Dekker (1994); pp. 47-68. [cited by applicant]
Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; (1998) pp. 37-47. [cited by applicant]
Haso et al., “Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymophoblastic leukemia,” Blood, vol. 121(No. 7):1165-1174, (2013). [cited by applicant]
Imabori Kazutomo, Biochemical Encyclopedia, 1998, 3rd Edition; pp. 265-266; including English translation. [cited by applicant]
Kapur et al., “IgG-effector functions: The Good, The Bad and The Ugly,” El Sevier, vol. 160:139-144, (2014). [cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, Landes Bioscience, 4(6):1-11, (2012). [cited by applicant]
Klinger et al., “Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab,” Blood, 119:6226-6233, (201… [cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” mAbs, Landes Bioscience, 4(2):182-197, (2012). [cited by applicant]
Köhnke et al., “Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab,” Journal of Hematoloty & Oncology, vol. 8 (No. 111):5 pages, (20… [cited by applicant]
Kumar et al., “Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia,” Indian J. Hematol Blood Transfus, vol. 30 (No. 1):16-18, (2014). [cited by applicant]
Kung et al., “Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens,” Science, 206:347-349, (1979). [cited by applicant]
Leonard et al., “Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma,” Semin Hematol, 45(suppl 2):S11-S16, (2008). [cited by applicant]
Liu et al., “Improvement in soluble expression levels of a diabody by exchanging expression vectors”, Protein Expression and Purification, 62:15-20, (2008). [cited by applicant]
Lum et al., “CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma,” Pbiol Blood Marrow Transplant, 19(6):925-933, (2013). [cited by applicant]
Lum et al., “Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study,” Bone Marrow Transplantation, 49:73-79, (2014). [Published online Sep. 23, 2013]. [cited by applicant]
Nagorsen et al., “Blinatumomab: A historical perspective,” Pharmacology & Therapeutics, 136:334-342 (2012). [cited by applicant]
NCBI MedGen 44126 definition for “Pre-B Acute Lymphoblastic Leukemia” retrieved from the Internet on Dec. 11, 2018; pp. 1-4, available at <https://www.ncbi.nlm.nih.gov/medgen/44126> (2018). [cited by applicant]
Ontology Lookup Serviec, EFO 0000220, “acute lumphoblastic leukemia” retrieved from the Internet on Dec. 11, 2018, pp. 1-6; available at <http://www.ebi.ac.uk/ols/ontologies/efo/terms?short_form=EFO_0000220> (2018). [cited by applicant]
Patel et al., “IGG subclass variation of a monoclonal antibody binding to human Fc-gamma receptors”, American Journal of Biochemistry and Biotechnology, 9(3):206-218, (2013). [cited by applicant]
Pessano et al., “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-0 and T3-) subunits,” The EMBO Journal, 4(2):337-344, (1985). [cited by applicant]
Ruf et al., “Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody,” Blood Journal, vol. 98, No. 9: 2526-2534, (2001). [cited by applicant]
Schuster et al., “Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies,” British Journal of Haematolgy, v… [cited by applicant]
Scott et al., “Antibody Therapy of Cancer,” Nature, vol. 12:278-287, (Apr. 2012). [cited by applicant]
Segal et al., “Bispecific antibodies in cancer therapy,” Current Opinion in Immunology, 11:558-562, (1999). [cited by applicant]
Siiman et al., “Cell Surface Receptor-Antibody Association Constants and Enumeration of Receptor Sites for Monoclonal Antibodies,” Cytometry, 40:316-326, (2000). [cited by applicant]
Smith et al., “A novel, native-format bispecific antibody triggering T-cell killing of B-cell is robustly active in mouse tumor models and cynomolgus monkeys,” Scientific Reports, vol. 5(No. 11):(Dec. 11, 2015); p. 1794… [cited by applicant]
Stanglmaier et al., “Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels”, Int. J. Cancer, 123(5… [cited by applicant]
Stel et al., “The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3,” J Immunol, 173(10):6009-6016, (2004). [cited by applicant]
Strop et al., “Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair”, J. Mol. Biol., 420(3):204-219, (2012). [cited by applicant]
Stubenrauch et al., “Impact of Molecular Processing in the Hinge Region of Therapeutic lgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys,” Drug Metabolism and Disposition, vol. 38(No. 1):84-91, (2010). [cited by applicant]
Sun et al., “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies,” Science Translational Medicine, 7(287):287ra70, 10 pages, (2015). [cited by applicant]
Teeling et al., “Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas,” Blood, 104:1793-1800, (2004). [cited by applicant]
Thakur et al., “Activated T cells from umbilical cord blood armed with anti-CD3 x anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for prov… [cited by applicant]
Thakur et al., “Cancer therapy with bispecific antibodies: Clinical experience,” NIH Public Access, Curr Opin Mol Ther., vol. 12(3): 340-349, (2010). [cited by applicant]
Thomas et al., “Chemiommunotherapy with a modified hyper-CVAD and Rituximab Regiment improves outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia,” Journal of Clinical On… [cited by applicant]
Topp et al., “Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leu, aemia: a multiventre, single-arm, phase 2 study,” The Lancet, vol. 16:57-66, (2015). [cited by applicant]
Tsai et al., “Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma,” Clinical Cancer Research, vol. 18(No. 4):1039-1050, (2012). [cited by applicant]
U.S. Appl. No. 14/031,075, Final Office Action mailed Sep. 14, 2016. [cited by applicant]
U.S. Appl. No. 14/031,075, Non-Final Office Action mailed Apr. 15, 2016. [cited by applicant]
U.S. Appl. No. 14/031,075, Notice of Allowance mailed Jan. 18, 2017. [cited by applicant]
U.S. Appl. No. 14/031,075, Requirement for Restriction/Election mailed Nov. 19, 2015. [cited by applicant]
U.S. Appl. No. 15/489,666, Non-Final Office Action mailed Feb. 11, 2020. [cited by applicant]
U.S. Appl. No. 15/489,666, Requirement for Restriction/Election mailed Jun. 18, 2019. [cited by applicant]
U.S. Appl. No. 15/934,447, Requirement for Restriction/Election mailed Oct. 17, 2019. [cited by applicant]
U.S. Appl. No. 15/934,447, Non-Final Office Action mailed May 8, 2020. [cited by applicant]
U.S. Appl. No. 15/489,666, Final Office Action mailed Sep. 10, 2020. [cited by applicant]
U.S. Appl. No. 15/934,447, Final Office Action mailed Dec. 4, 2020. [cited by applicant]
U.S. Appl. No. 15/489,666, Notice of Allowance mailed Mar. 24, 2021. [cited by applicant]
U.S. Appl. No. 15/934,447, Notice of Allowance mailed Jun. 24, 2021. [cited by applicant]
U.S. Appl. No. 16/556,885, Non-Final Office Action mailed Mar. 29, 2022. [cited by applicant]
U.S. Appl. No. 17/355,532, Non-Final Office Action mailed May 19, 2023. [cited by applicant]
Van Meerten et al., “CD20-Targeted Therapy: The Next Generation of Antibodies,” Semin Hematol, 47:199-210, (2010). [cited by applicant]
Varghese et al., “A Novel CD20-CD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice,” Blood, vol. 124 (21) 4501 (2014). [http://doi.org/10.1182/blood.V124.21.4501.4501]. [cited by applicant]
Wark et al., “Latest technologies for the enhancement of antibody affinity”, Advanced Drug Delivery Reviews, 58(5-6):657-670, (2006). [cited by applicant]
Winkler et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J. Immunol., 165:4505-4514, (2000). [cited by applicant]
WIPO Application No. PCT/US2013/060511, PCT International Search Report and Written Opinion of the International Searching Authority mailed Feb. 20, 2014. [cited by applicant]
WIPO Application No. PCT/US2015/021322, PCT International Search Report and Written Opinion of the International Searching Authority mailed Jul. 2, 2015. [cited by applicant]
Wolach et al., “Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia,” Clinical Cancer Research, vol. 21 (No. 19):4262-4269, (2015). [cited by applicant]
Xiong et al., “Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody”, Cancer Letters, 177:29-39, (2002). [cited by applicant]
Yuen et al., “B lymphocytes and cancer: a love-hate relationship,” Trends Cancer Dec. 2016; 2(12): 747-757. [cited by applicant]
U.S. Appl. No. 61/704,029, filed Sep. 21, 2012, Expired. [cited by applicant]
U.S. Appl. No. 61/753,461, filed Jan. 17, 2013, Expired. [cited by applicant]
U.S. Appl. No. 61/763,110, filed Feb. 11, 2013, Expired. [cited by applicant]
U.S. Appl. No. 61/827,098, filed May 24, 2013, Expired. [cited by applicant]
U.S. Appl. No. 14/031,075, filed Sep. 19, 2013, U.S. Pat. No. 9,657,102, Issued. [cited by applicant]
U.S. Appl. No. 15/489,666, filed Apr. 17, 2017, U.S. Pat. No. 11,072,656, Issued. [cited by applicant]
PCT/US2013/060511, Sep. 19, 2013, WO 2014/047231, Expired. [cited by applicant]
U.S. Appl. No. 15/934,447, filed Mar. 23, 2018., U.S. Pat. No. 11,155,621, Issued. [cited by applicant]
U.S. Appl. No. 17/355,532, filed Jun. 23, 2021, US-2022-0144947, Abandoned. [cited by applicant]
U.S. Appl. No. 61/955,663, filed Mar. 19, 2014, Expired. [cited by applicant]
U.S. Appl. No. 61/981,641, filed Apr. 18, 2014, Expired. [cited by applicant]
U.S. Appl. No. 62/007,385, filed Jun. 3, 2014, Expired. [cited by applicant]
U.S. Appl. No. 62/033,460, filed Aug. 5, 2014, Expired. [cited by applicant]
U.S. Appl. No. 14/661,334, filed Mar. 18, 2015, U.S. Pat. No. 10,550,193, Issued. [cited by applicant]
PCT/US2015/021322, Mar. 18, 2015, WO 2015/143079, Expired. [cited by applicant]
U.S. Appl. No. 16/716,980, filed Dec. 17, 2019, U.S. Pat. No. 11,434,300, Issued. [cited by applicant]
U.S. Appl. No. 17/875,295, filed Jul. 27, 2022, US-2023-0220101, Published. [cited by applicant]
U.S. Appl. No. 62/080,716, filed Nov. 17, 2014, Expired. [cited by applicant]
U.S. Appl. No. 62/160,788, filed May 13, 2015, Expired. [cited by applicant]
PCT/US2015/061139, Nov. 17, 2015, WO 2016/081490, Expired. [cited by applicant]
U.S. Appl. No. 15/527,002, filed Nov. 17, 2015, U.S. Pat. No. 10,662,244, Issued. [cited by applicant]
U.S. Appl. No. 62/306,031, filed Mar. 9, 2016, Expired. [cited by applicant]
U.S. Appl. No. 15/386,443, filed Dec. 21, 2016, US 2017-0174781, Abandon. [cited by applicant]
PCT/US2016/068003, Dec. 21, 2016, WO 2017/112762, Expired. [cited by applicant]
U.S. Appl. No. 16/556,885, filed Aug. 30, 2019, U.S. Pat. No. 11,590,223, Issued. [cited by applicant]
U.S. Appl. No. 62/726,137, filed Aug. 31, 2018, Expired. [cited by applicant]
U.S. Appl. No. 62/774,019, filed Nov. 30, 2018, Expired. [cited by applicant]
U.S. Appl. No. 62/861,100, filed Jun. 13, 2019, Expired. [cited by applicant]
PCT/US2019/049027, Aug. 30, 2019, WO 2020/047389, Expired. [cited by applicant]
U.S. Appl. No. 18/101,310, filed Jan. 25, 2023, US-2023-0165959, Published. [cited by applicant]
U.S. Appl. No. 63/313,932, filed Feb. 25, 2022, Expired. [cited by applicant]
U.S. Appl. No. 63/393,212, filed Jul. 28, 2022, Expired. [cited by applicant]
U.S. Appl. No. 63/420,782, filed Oct. 31, 2022, Expired. [cited by applicant]
U.S. Appl. No. 63/424,210, filed Nov. 10, 2022, Expired. [cited by applicant]
U.S. Appl. No. 63/440,304, filed Jan. 20, 2023, Expired. [cited by applicant]
U.S. Appl. No. 18/114,057, filed Feb. 24, 2023, US-2023-0272118. [cited by applicant]
PCT/US2023/013836, Feb. 24, 2023, WO2023/164143, Published. [cited by applicant]
U.S. Appl. No. 17/875,295, Non-Final Office Action mailed Mar. 13, 2025. [cited by applicant]
Chao et al. (Cancer Management and Research 2013:5 251-269). (Year: 2013). [cited by applicant]
Wong et al. (Haematologica. Dec. 2013 98(12):1930-1938, supplemental pages included, document has been renumbered as pp. 1-27). (Year: 2013). [cited by applicant]
P01834 (GenPept, Ig kappa chain C region, pp. 1-4, Feb. 19, 2014). (Year: 2014). [cited by applicant]